Jianfeng Group Lin2016 -026 (Announcement on Foreign Investment of Subsidists)
Release time:
2020-08-05
证券代码:600668 证券简称:尖峰集团 公告编号:2016-026
债券简称:13尖峰01 债券代码:122227
债券简称:13尖峰02 债券代码:122344
浙江尖峰集团股份有限公司
关于子公司对外投资的公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示:
l 本公司控股子公司浙江尖峰药业有限公司与德国葛芙制药有限公司、珠海横琴德运嘉国际贸易有限公司签订了《中外合资经营企业合同》,拟在中国浙江省金华市共同出资设立一家中外合资经营企业,致力于建成一个婴幼儿、儿童用药的制药企业。
l 尖峰药业本次拟出资人民币1100万元,占合营公司注册资本的55%。
l 合营公司的成立尚需相关政府商务部门的批准;合营公司成立后的运营团队组织与磨合、产品研发、产品上市销售情况等事项都存在一定的不确定性风险。
一、对外投资概述
(一)2016年7月12日,本公司控股子公司浙江尖峰药业有限公司(以下简称:尖峰药业)与德国葛芙制药有限公司(以下简称:葛芙制药)、珠海横琴德运嘉国际贸易有限公司(以下简称:德运嘉)签订了《中外合资经营企业合同》,合营各方根据平等互利的原则和长期真诚合作的愿望,努力吸取各自专长和采用适宜的先进技术以及科学的管理方法成立合营公司,并致力于建成一个以婴幼儿、儿童用药制剂研发、生产和销售为主的现代化制药企业。
合营公司中文名称是:浙江金得尔儿婴药品有限公司(以下简称“合营公司”)(以工商行政管理部门核定的名称为准)。合营公司的注册资本为人民币2000万元,其中:尖峰药业以现金人民币1100万元出资,葛芙制药以专有技术的知识产权评估作价人民币500万元出资,德运嘉以现金人民币400万元出资。合营公司拟注册在中国浙江省金华市金西开发区。
(二)本次对外投资,尖峰药业的出资金额为人民币1100万元,根据本公司《章程》有关规定,在董事长对外投资审批权限范围之内,无需提交公司董事会、股东大会审议。
(三)该合作事项不属于关联交易,也不构成《上市公司重大资产重组管理办法》规定的重大资产重组情况。
二、协议主题的基本情况
(一)德国葛芙制药有限公司
1、企业名称:德国葛芙制药有限公司(GOHOFF ARZNEIMITTEL GmbH)
2、企业性质:有限责任公司
3、注册地:德国柏林
4、注册日期:2016年3月24日
5、主要办公地点:德国柏林茵塞尔路17号
6、法定代表人:Katharina Bodmeier
7、注册资本:25000欧元
8、主营业务:药品、化学品、化妆品和保健品的开发、销售和贸易
9、主要股东:
|
序号 |
股东名称或姓名 |
出资额(欧元) |
出资比例 |
|
1 |
Prof.Dr.Roland Bodmeier |
12500 |
50% |
|
2 |
FangHuang |
11250 |
45% |
|
3 |
Katharina Bodmeier |
1250 |
5% |
(二)珠海横琴德运嘉国际贸易有限公司
1、企业名称:珠海横琴德运嘉国际贸易有限公司
2、企业性质:有限责任公司(自然人独资)
3、注册地:珠海市横琴新区
4、注册日期:2015年06月17日
5、主要办公地点:珠海市横琴新区宝华路6号105室-3754
6、法定代表人:李华智
7、注册资本:500万元人民币,截止公告日实收资本为240万元。
8、主营业务:从事货物与技术的进出口业务;贸易咨询、技术咨询、技术服务;化妆品及卫生用品进出口批发和零售;非许可类医疗器械经营;医疗用品和器材进出口批发和零售;草药和天然产品的进出口批发和零售;保健食品、乳制品进出口批发和零售;动物用健康食品、保健品和药品的进出口批发和零售;药品进出口批发和零售;预包装食品的批发和销售。
9、主要股东:李华智先生占公司注册资本100%。
10、主要财务指标:截止2015年12月31日,德运嘉的资产总额为27.35万元、资产净额5.93万元、营业收入48.54万元、净利润-4.07万元等;
三、合营公司的基本情况
1、企业名称:浙江金得尔儿婴药品有限公司(以工商行政管理部门核定的名称为准)
2、经营范围:保健品和药品进出口,研究、开发、生产和销售婴幼儿用药及其他生物及化学医药产品。
3、注册资本:2000万元人民币
4、出资方式:尖峰药业以现金出资人民币1100万元,占注册资本的55%;葛芙制药以“地西泮栓”、“对乙酰氨基酚栓”两项专有技术评估作价人民币500万元出资,占注册资本的25%;德运嘉以现金出资人民币400万元出资,占注册资本的20%。
5、董事会安排:合营公司董事会由5名董事组成,尖峰药业委派3人,葛芙制药委派1人,德运嘉委派1人。董事长由尖峰药业委派担任,副董事长由葛芙制药委派。董事长、副董事长和董事的任职期限应为四年。
6、管理层安排:合营公司设总经理1名和财务经理1名。总经理由葛芙制药委派,财务经理由尖峰药业委派,任期为四年。
7、无形资产出资情况:葛芙制药以其拥有的“地西泮栓”、“对乙酰氨基酚栓”两项专有技术作价500万元人民币进行出资。金华金辰资产评估有限公司对上述两项专有技术进行评估并出具了《评估报告》,评估价值为555.00万元(大写人民币伍佰伍拾伍万元)。葛芙制药所拥有的“地西泮栓”、“对乙酰氨基酚栓”两项专有技术不存在抵押、质押或者其他重大争议、诉讼或仲裁事项、查封或者冻结等司法措施。
地西泮栓是用于抗焦虑、睡眠障碍,增加肌肉张力的治疗药物;对乙酰氨基酚是用于感冒或感冒引起的发热,也用于缓解轻至中度疼痛。“地西泮栓”、“对乙酰氨基酚栓”都已经在德国上市。中国国家食品药品监督管理总局的网站显示已经有54个“对乙酰氨基酚栓”的批准文号;尚未有“地西泮栓”的批准文号, 但“地西泮”片剂、注射剂已经有较多的批准文号。合资公司成立后将以上述两项专有技术为基础进行相应产品的研发、经营。
四、合同的主要内容
2016年7月12日,尖峰药业(甲方)、葛芙制药(乙方)和德运嘉(丙方)签订了《中外合资经营企业合同》,主要条款有:
1、甲方、乙方和丙方三方将根据《中华人民共和国中外合资经营企业法》、《中华人民共和国中外合资经营企业法实施条例》等其他与本合同相关的法律、法规和规定,按照平等互利的原则,通过友好协商,一致同意在中国浙江省金华市共同设立中外合资经营企业。
2、合营公司注册资本为人民币2000万元。甲方出资额占注册资本的55%,其中以现金出资人民币1100万元。乙方出资额占注册资本的25%,其中以知识产权出资,以评估作价出资人民币500万元。丙方出资额占注册资本的20%,其中以现金出资人民币400万元。
3、以现金出资时,甲、丙双方应于2017年6月30日前缴付认缴的出资;以知识产权出资时,乙方应在公司成立之日起180工作日内,办理知识产权变更登记,将出资用知识产权所有权和使用权转移至合营公司。
4、合营公司租用甲方拥有的位于金华金西开发区尖峰药业制药基地内厂房。甲方同意该场地可用以建成合营公司的药品研发、生产基地。场地租金须不高于市场价,租赁协议另行签订。租赁期限应为中国法律允许的最长期限20年。
5、董事会是合营公司最高权力机构,合营公司的营业执照颁发之日为其董事会成立之日。合营公司的重大事项应由董事会全体一致决定。对于下列事项应由董事会全体董事一致通过方可做出决定:(1)合营企业章程的修改;(2)合营企业的中止、提前终止、解散、清算或延长合营公司期限;(3)合营企业注册资本的增加和减少;(4)合营企业的合并和分立;(5)合营各方向合营公司外的其他方转让股权。
除上述条款外的其它事项应由多数票通过决议决定,但是至少乙方或丙方委派的一名董事投了赞成票。
6、合营公司设总经理1 名和财务经理1 名。总经理应由乙方委派,财务经理应由甲方委派。他们的任期为四年,同样可根据董事会的决定连任。合营公司的其他高层管理人员,由总经理提议,董事会批准后聘请。
7、合营公司的合营期限为30年,从合营公司营业执照签发之日开始。
8、若合资公司决定解散,需进行清算。在制定和执行清算方案的过程中,清算委员会应尽可能将合营公司的产品、产品开发权益、知识产权、专有技术等分配给乙方和/或丙方。
9、除因不可抗力外,若本合同一方在实质性方面不完整、不恰当履行或终止履行本合同,在收到合营其他方通知后六十天内仍不纠正其违约行为时,该方便构成违约,违约方应承担责任,负责赔偿履约方或合营公司由此遭受的损失,赔偿上限不超过认缴的出资额或以非货币财产出资时的非货币财产。
10、本合同的效力,解释,执行,修改,终止及争议的解决,应适用中国法律。已公布的中国法律未涉及事宜,采用国际惯例。
11、在履行本合同及附件过程中发生的一切争议,各方首先应友好协商解决,如争议各方不能协商解决,则经各方书面同意,可将争议提交中国国际经济贸易仲裁委员会按其仲裁程序进行仲裁。仲裁语言采用中文,翻译成英文。仲裁裁决是终局的,并对各方均有约束力。
12、本合同自合营各方签字盖章,并经有权的审批机构批准后生效。
五、对公司的影响
随着我国人口政策的调整,“全面二胎”政策的实施,预计婴幼儿用药市场将迎来快速增长的机遇,本次尖峰药业通过组建合营公司,引进德国技术开发婴幼儿用药,符合公司的发展战略规划,是公司做大做强医药业务的具体实施。
六、可能存在的风险
本次签署的是《中外合资经营企业合同》,合营公司的成立尚需相关政府商务部门的批准;合营公司成立后的运营团队组织与磨合、产品研发、产品上市销售情况等事项都存在一定的不确定性风险。
敬请广大投资者注意投资风险。
特此公告
浙江尖峰集团股份有限公司董事会
二〇一六年七月十二日
More information
Teachers and Students of Zhejiang Gongshang University Visit Peak Health
News from our newspaper On the morning of June 9, a group of 18 teachers and students from Zhejiang Gongshang University came to Jianfeng Health for a visit and discussion, and conducted research on the establishment of Zhejiang Gongshang University Food Industrialization Research Institute in Jinhua. The leader of this visit is Professor Song Guanglei from the School of Food and Biological Engineering, Zhejiang Gongshang University. The teachers and students are mainly from the School of Food and Engineering, specializing in food science, food safety, biochemical and biotechnology, focusing on extraction and separation, functional activity and The research of functional food, in addition to the professor of the Department of E-commerce of the School of Management Engineering and E-commerce. Chen Daiyou, general manager of Jianfeng Health, Li Wende, deputy general manager, and relevant personnel from R & D, quality management, administrative personnel and other departments attended the forum. Li Wende introduced the basic situation, technical production level, scientific and technological research and development characteristics of Jianfeng Health Company in the form of PPT, as well as the relevant policies of Jinhua Municipal Government on talent introduction. Chen Daiyou focused on the development vision of Jianfeng Health Technology and the construction of scientific and technological talents, and welcomed graduate students from the Industrial and Commercial University to join the team of Jianfeng Health after graduation. Professor Song Guanglei fully affirmed the software and hardware facilities and humanistic management of Jianfeng Health Company. He said that most of the teachers and students who came to visit this time were professional in line with the industry of Jianfeng Health Company. The two sides could carry out in-depth cooperation in product development, technology upgrading and talent reserve. Fourteen graduate students also introduced their respective situations and study and research directions. After the symposium, the teachers and students visited the health company's testing center, R & D laboratory and plant extraction workshop with great interest.
2020
07-31
Trial operation of large pharmacy micro-mall
The construction of the micro-mall of Jianfeng Pharmacy is basically ready at present. On June 17, Shuangxi and Donglai chain stores took the lead in the trial operation of the micro-mall. At present, online consumption through computers and mobile phones has become a way of life in China. In particular, various software represented by WeChat covers more than 90% of smart phones, and has many functions such as information exchange and online payment. It is a new type of shopping system based on WeChat platform, using mobile Internet technology to realize the integration of online and offline marketing. At present, there are more than 1000 kinds of commodities on the shelves of the micro-mall of Jianfeng pharmacy, mainly OTC commodities of over-the-counter drugs, which are basically synchronized with pharmacies. Customers only need to pay attention to the public number of Jianfeng Pharmacy and enter the micro-mall to collect coupons through the "online drug purchase" on the public number page. They can find the required drugs on the mobile phone to purchase and pay for them. The delivery method can be delivered to the door or the store can pick them up by itself. The purchase of drugs through the micro-mall is not only convenient and fast, but also can reduce the phenomenon of queuing in the store. According to reports, the opening of the micro mall by the big pharmacy is to expand the new service model and provide more and better extended services to the masses. Prior to this, the WeChat public number of the large pharmacy has already made a useful attempt to push health information, and the operation of the micro-mall will further provide users with new channels for seeking medical advice. While further improving the micro-mall system, the large pharmacy will add "online pharmacists" and other service items to provide users with real-time consulting services such as medication guidance, drug purchase recommendation, health care knowledge and so on in the form of voice or text. (Tang Wenshu)
2020
07-31
Spike Health gets patent grants
Recently, Jianfeng Health Technology Company's invention patent "a low-temperature and low-pressure freeze-drying method for notoginseng chewable tablets" won a patent subsidy from Jinhua Science and Technology Bureau in 2017. In order to encourage invention and creation, promote independent innovation, promote the development of patented technology and products, and speed up the transformation of patent achievements, Jinhua Science and Technology Bureau gives invention patent subsidies to enterprises within its jurisdiction every year. Patent subsidies are declared once a year. After authorization, each domestic invention patent can receive a subsidy of 40000 yuan, including 20000 yuan in Jinhua City and 20000 yuan in the district. The invention patent of spike health "a low-temperature and low-pressure freeze-drying method of notoginseng chewable tablets" obtains notoginseng chewable tablets by washing, slicing and other pretreatment of fresh notoginseng main roots, then placing them in a vacuum dryer for vacuum freeze-drying. As the top high and new technology in the field of dehydration products, the whole freeze-drying process is carried out at low temperature, which avoids the quality deterioration reactions such as oxidation of active ingredients, destruction of volatile oil and other heat-sensitive substances in the traditional drying process. It can maximize the retention of various nutrients and active substances of medicinal materials and perfectly reproduce its initial type, color and taste, it has the characteristics of light weight, fast rehydration, convenient consumption and long storage period. The actual effect, appearance and color are basically the same as those of fresh Panax notoginseng. The effective ingredients are about 50% higher than those of products processed by traditional processes such as drying and drying. It is understood that the 2017 Jinhua patent subsidy of 20000 yuan obtained by Jianfeng Health is currently in place, and the application of patent subsidy in Wucheng District is in progress. (Xu Feng)
2020
07-31
Spike Health gets patent grants
Recently, Jianfeng Health Technology Company's invention patent "a low-temperature and low-pressure freeze-drying method for notoginseng chewable tablets" won a patent subsidy from Jinhua Science and Technology Bureau in 2017. In order to encourage invention and creation, promote independent innovation, promote the development of patented technology and products, and speed up the transformation of patent achievements, Jinhua Science and Technology Bureau gives invention patent subsidies to enterprises within its jurisdiction every year. Patent subsidies are declared once a year. After authorization, each domestic invention patent can receive a subsidy of 40000 yuan, including 20000 yuan in Jinhua City and 20000 yuan in the district. The invention patent of spike health "a low-temperature and low-pressure freeze-drying method of notoginseng chewable tablets" obtains notoginseng chewable tablets by washing, slicing and other pretreatment of fresh notoginseng main roots, then placing them in a vacuum dryer for vacuum freeze-drying. As the top high and new technology in the field of dehydration products, the whole freeze-drying process is carried out at low temperature, which avoids the quality deterioration reactions such as oxidation of active ingredients, destruction of volatile oil and other heat-sensitive substances in the traditional drying process. It can maximize the retention of various nutrients and active substances of medicinal materials and perfectly reproduce its initial type, color and taste, it has the characteristics of light weight, fast rehydration, convenient consumption and long storage period. The actual effect, appearance and color are basically the same as those of fresh Panax notoginseng. The effective ingredients are about 50% higher than those of products processed by traditional processes such as drying and drying. It is understood that the 2017 Jinhua patent subsidy of 20000 yuan obtained by Jianfeng Health is currently in place, and the application of patent subsidy in Wucheng District is in progress. (Xu Feng)
2020
07-30
Spike Health gets patent grants
Recently, Jianfeng Health Technology Company's invention patent "a low-temperature and low-pressure freeze-drying method for notoginseng chewable tablets" won a patent subsidy from Jinhua Science and Technology Bureau in 2017. In order to encourage invention and creation, promote independent innovation, promote the development of patented technology and products, and speed up the transformation of patent achievements, Jinhua Science and Technology Bureau gives invention patent subsidies to enterprises within its jurisdiction every year. Patent subsidies are declared once a year. After authorization, each domestic invention patent can receive a subsidy of 40000 yuan, including 20000 yuan in Jinhua City and 20000 yuan in the district. The invention patent of spike health "a low-temperature and low-pressure freeze-drying method of notoginseng chewable tablets" obtains notoginseng chewable tablets by washing, slicing and other pretreatment of fresh notoginseng main roots, then placing them in a vacuum dryer for vacuum freeze-drying. As the top high and new technology in the field of dehydration products, the whole freeze-drying process is carried out at low temperature, which avoids the quality deterioration reactions such as oxidation of active ingredients, destruction of volatile oil and other heat-sensitive substances in the traditional drying process. It can maximize the retention of various nutrients and active substances of medicinal materials and perfectly reproduce its initial type, color and taste, it has the characteristics of light weight, fast rehydration, convenient consumption and long storage period. The actual effect, appearance and color are basically the same as those of fresh Panax notoginseng. The effective ingredients are about 50% higher than those of products processed by traditional processes such as drying and drying. It is understood that the 2017 Jinhua patent subsidy of 20000 yuan obtained by Jianfeng Health is currently in place, and the application of patent subsidy in Wucheng District is in progress. (Xu Feng)
2020
07-31
On May 27, the Party Committee of the Group Company held a branch secretary meeting to comprehensively review and summarize the Party building work of the Company in 2016 and sign the responsibility book for the management of Party building work objectives in 2017. At the meeting, Qin xuping, member of the party Committee of the group company and director of the party-mass work department, made a comprehensive summary of the company's party building work in 2016, put forward the 2017 work plan, and conveyed the "key points of party building work in the city's two new organizations in 2017" issued by the two new working committees of Jinhua municipal party Committee, and the spirit of the speech made by the relevant leaders of the municipal party Committee at the recent meeting of the city's two new working committee, this paper explains the "ten questions" of the two new grass-roots party organizations, the "ten questions" of Party members and some problems that need attention in the process of Party member development. Members of the party committee of the group company, secretaries of grass-roots party committees and branch secretaries expressed their views and conducted extensive exchanges on such topics as how to deepen the "two learning and one doing", further play the role of party organizations in the process of enterprise operation and management, and how to do a good job in organizational construction in 2017. Jiang Xiaomeng, secretary of the party committee and chairman of the group company, on behalf of the party committee of the group, signed the 2017 party building work target management responsibility letter with the heads of the party organizations of various professional companies and directly affiliated enterprises. In his speech at the meeting, Jiang Xiaomeng said that the Politburo meeting of the CPC Central Committee held on the 26th reviewed and approved the "Decision on Amending the Regulations on the Inspection Work of the Communist Party of China" and other reports, which is a major measure to further implement the provisions of the party constitution and strengthen internal party supervision. Specific to the internal party building work of the enterprise, all cadres and party members should earnestly study relevant policies and documents, and earnestly understand the spirit of the central government
2020
07-31